Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Pfizer Inc.NYSE: PFE

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA declines year over year

Q2 FY2026 EBITDA of $1.64B fell 69.3% year over year, behind the -33.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 70.0% from the prior quarter. Over 3 fiscal years it compounded at -25.8% a year.

Context

  • EBITDA amounted to 26.8% of revenue in FY2025, down 1.7 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 18 analysts of $30.62B (+82.4%) for the fiscal year ending Dec 2026, a step up from the -7.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.64B-70.0% QoQ
Last fiscal yearDec 2025
$16.78B-7.4% YoY
LTMJun 2026
$13.49B-33.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.3%+34.4%+103.7 pp
1 year-7.4%+82.4%+89.9 pp
3-year CAGR-25.8%+14.6%+40.4 pp
5-year CAGR+6.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
16.78B USD
Year-over-year change
-7.4%
4-year CAGR
-14.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PFE compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.1% is the 9th highest of 11, against a peer median of +6.9%.
  • EBITDA amounts to 21.2% of revenue for PFE, versus a peer median of 32.6%.
PFE Competitors
EBITDA for PFE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$43.3B USD+103.7%+54.1%54.4%
JNJJohnson & JohnsonLTM Sep 2026$30.81B USD-22.1%+15.6%31.0%
ABBVAbbVie Inc.LTM Sep 2026$24.15B USD+88.7%-10.0%36.6%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$16.82B USD+11.6%-7.5%34.2%
SNYSanofiLTM Jun 2026€14.77B EUR+15.5%-2.6%30.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
GSKGSK plcLTM Jun 2026£8.8B GBP+2.2%+6.5%26.5%
GILDGilead Sciences, Inc.LTM Jun 2026$1.33B USD-87.8%+15.3%4.4%
Peer median (excluding PFE) —+6.9%+12.6%32.6%

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.29B101.18B59.55B63.63B62.58B
Cost of Revenue30.82B34.34B24.95B17.85B16.07B
Gross Profit50.47B66.83B34.6B45.78B46.51B
Gross Margin62.1%66.1%58.1%71.9%74.3%
Research & Development13.83B11.43B10.68B10.82B10.44B
Selling, General & Admin12.7B13.68B14.77B14.73B13.79B
Operating Expenses30.23B28.71B30.18B30.84B29.11B
Depreciation & Amortization5.19B5.06B6.29B7.01B6.59B
EBITDA30.79B41.03B9.56B18.13B16.78B
EBITDA Margin37.9%40.6%16.0%28.5%26.8%
Operating Income20.24B38.12B4.42B14.94B17.41B
Operating Margin24.9%37.7%7.4%23.5%27.8%
Interest Income36M251M1.62B545M603M
Interest Expense1.29B1.24B2.21B3.09B2.67B
Other Income / Expenses4.08B(3.39B)(3.36B)(6.92B)(9.89B)
Income Before Tax24.31B34.73B1.06B8.02B7.52B
Pre-Tax Margin29.9%34.3%1.8%12.6%12.0%
Income Tax Expense1.85B3.33B(1.12B)(28M)(266M)
Net Income21.98B31.37B2.12B8.03B7.77B
Net Margin27.0%31.0%3.6%12.6%12.4%
EPS (Basic)3.955.590.381.421.36
EPS (Diluted)3.885.470.371.411.36
Weighted Avg Shares5.6B5.61B5.64B5.66B5.68B
Weighted Avg Shares (Diluted)5.71B5.73B5.71B5.7B5.69B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.